Yu Zhang - research works

Semi-structured interviews with 5 respiratory medical staff identified the core stages of the patient journey.

In a separate subsequent process, the 8 experts selected for consultation had an average work experience of 19.13 ± 3.27 years.

Education levels included 2 with a bachelor's degree and 6 with a master's degree or above; professional titles included 3 associate senior doctors, 3 senior doctors and 2 intermediate doctors; and research specialties included 5 in respiratory medicine and 3 in internal medicine nursing.

Among 1013 patients with SjD, 52.6% exhibited hypocomplementemia.

At baseline, patients with hypocomplementemia had higher disease activity and a greater prevalence of immunological abnormalities, including hyper-IgG and positivity for anti-SSA, anti-SSB, and anti-Ro52 antibodies, as well as more frequent peripheral cytopenias (including leukopenia, neutropenia, lymphocytopenia, erythrocytopenia, anemia, and thrombocytopenia).

Random-effects meta-analyses were used to pool prevalence estimates of polypharmacy based on mixed thresholds and relative risks.

It demonstrated a significant increasing temporal trend in polypharmacy prevalence over calendar years.

Dose-response meta-analyses showed a monotonic increase in risk with each additional medication for mortality (HR: 1.05, 95% CI: 1.03-1.06, p < .001), emergency (HR: 1.02, 95% CI: 1.02-1.03, p < .001), and hospital admission (HR: 1.04, 95% CI: 1.02-1.07, p < .001).

Outcome-specific thresholds ranged from 4.55 to 5.46 medications.

Multivariable logistic regression adjusted for maternal weight and ELA duration confirmed that longer ELA interruption time was independently associated with reduced odds of ESA failure (OR = 0.986, 95% CI 0.977-0.996, P = 0.006).

The MRI study revealed that at 2 h post-delivery, compared with 24 h post-delivery, the DS area was significantly reduced and the ES area was significantly enlarged at all lumbar levels.

Epidural fluid accumulation was observed in 18.2% of parturients at 2 h.

No significant differences in spinal ganglion ADC values were detected, indicating no neural edema.

Baseline characteristics were well-balanced between groups after weighting.

No significant between-group differences were observed in PSI or ASEI.

The results of all sensitivity analyses were consistent with those of the primary analysis.

Combining four tasks increased Recall to 1.0 with high level Accuracy, F1-score, and AUC.

However, adding more movements (5-8 tasks) did not improve model performance.

Among different model configurations, RCIRNet performed best, SVM demonstrated overall stability, and KNN excelled in Recall.

Patients were divided into a derivation cohort (n=209) and an external validation cohort (n=52).

85 patients (32.57%) were MVI-positive.

Calibration curves revealed excellent agreement between the model's predicted probability of MVI and the actual observed outcomes.

DCA confirmed the excellent net benefits.

The prevalence of VAP was 9.6% (48/502 patients).

The constructed Bayesian network included 10 nodes and 17 directed edges.

Direct associations with VAP were identified for antibiotic use exceeding three agents, reintubation, mechanical ventilation methods, and an Acute Physiology and Chronic Health Evaluation II (APACHE II) score ≥ 15.

Among the 5,026 screened students, 160 AIS cases were confirmed among 185 rescreen-positive students, and 2 additional AIS cases were identified among 300 randomly verified screen-negative students.

Thoracic curves and Cobb angles of 10°- < 20° were most common.

Girls and middle school students had higher crude radiographic detection rates than boys and primary school students, respectively.

The AI-assisted structured-light screening workflow showed IPW-adjusted sensitivity of 0.832, specificity of 0.995, PPV of 0.865, NPV of 0.993, and overall accuracy of 0.989.

While most investigational KRAS-G12D inhibitors are oral small molecules limited by gastrointestinal toxicities and suboptimal tumor exposure, HRS-4642 is a new, high‑affinity, noncovalent KRAS-G12D inhibitor.

This phase 1b/2 study evaluated HRS-4642 in combination with nab-paclitaxel and gemcitabine (AG) in patients with advanced KRAS G12D -mutant PDAC.

Grade ≥3 treatment-related adverse events (TRAEs) occurred in 90.3% patients, primarily hematologic toxicities consistent with AG chemotherapy.

Clinicaltrials.gov registration: NCT06520488 .

At week 24, 8 participants (88.9%) exhibited a reduction in HDV RNA ≥1 log10 from baseline, with 4 (44.4%) achieving undetectable levels.

Among the 5 participants with elevated baseline ALT, 3 (60.0%) achieved a combined virological and biochemical response (ALT normalization).

At week 48, 6 participants (66.7%) maintained the virological response achieved at the end of treatment (week 24), with 3 (33.3%) maintaining undetectable HDV RNA levels.

Among the 7 participants with quantifiable HBV DNA at baseline, 2 (28.6%) achieved undetectable HBV DNA or ≥1 log10 reduction at week 24.